Cardiac Biotech Solutions（CBSC）株式概要Cardiac Biotech Solutions Inc.は、その子会社を通じて、外来非侵襲的心臓モニタリング分野における様々な製品とサービスを米国内外で提供している。 詳細CBSC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $5M )すべてのリスクチェックを見るCBSC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.035.1k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-948k50k2016201920222025202620282031Revenue US$50.4kEarnings US$7.4kAdvancedSet Fair ValueView all narrativesCardiac Biotech Solutions Inc. 競合他社RedHill BiopharmaSymbol: NasdaqCM:RDHLMarket cap: US$5.0mReviva Pharmaceuticals HoldingsSymbol: OTCPK:RVPHMarket cap: US$5.3mPulmatrixSymbol: NasdaqCM:PULMMarket cap: US$4.9mAnanda PharmaSymbol: OTCPK:ANAN.FMarket cap: US$4.9m価格と性能株価の高値、安値、推移の概要Cardiac Biotech Solutions過去の株価現在の株価US$0.0352週高値US$0.06352週安値US$0.016ベータ01ヶ月の変化-25.00%3ヶ月変化-49.15%1年変化-40.24%3年間の変化-80.00%5年間の変化-94.44%IPOからの変化-97.65%最新ニュースお知らせ • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.お知らせ • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.お知らせ • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.お知らせ • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.お知らせ • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.お知らせ • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.最新情報をもっと見るRecent updatesお知らせ • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.お知らせ • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.お知らせ • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.お知らせ • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.お知らせ • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.お知らせ • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.お知らせ • Oct 10CB Scientific, Inc. Announces the Launch of My-Cardia ECG Products and Services in ThailandCB Scientific. Inc. announces the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician. The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed. CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.お知らせ • Sep 24CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp.CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020. CB Scientific, Inc. (OTCPK:CBSC) completed the acquisition of Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.株主還元CBSCUS PharmaceuticalsUS 市場7D-6.3%5.4%1.2%1Y-40.2%44.3%28.7%株主還元を見る業界別リターン: CBSC過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: CBSCは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is CBSC's price volatile compared to industry and market?CBSC volatilityCBSC Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のCBSCのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aChip Martincardiacbiotech.comCardiac Biotech Solutions Inc.は、その子会社を通じて、外来非侵襲的心臓モニタリングの分野で様々な製品とサービスを米国内外で提供している。同社の心電図機器、対話型クラウドベース収集ソフトウェア、スマートフォンアプリは、異常な心臓リズムのリスクを抱える患者にコンプライアンスを強化し、医師にも正確な情報を提供する。同社の前身はCB Scientific, Inc.で、2025年5月に社名をCardiac Biotech Solutions Inc.に変更した。本社はネバダ州ラスベガス。もっと見るCardiac Biotech Solutions Inc. 基礎のまとめCardiac Biotech Solutions の収益と売上を時価総額と比較するとどうか。CBSC 基礎統計学時価総額US$5.11m収益（TTM）-US$640.55k売上高(TTM)US$50.37k0.0xP/Sレシオ0.0xPER（株価収益率CBSC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CBSC 損益計算書（TTM）収益US$50.37k売上原価US$23.00k売上総利益US$27.37kその他の費用US$667.92k収益-US$640.55k直近の収益報告Dec 31, 2018次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%CBSC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 04:05終値2026/05/22 00:00収益2018/12/31年間収益2018/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cardiac Biotech Solutions Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.
お知らせ • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.
お知らせ • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.
お知らせ • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.
お知らせ • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.
お知らせ • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.
お知らせ • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.
お知らせ • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.
お知らせ • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.
お知らせ • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.
お知らせ • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.
お知らせ • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.
お知らせ • Oct 10CB Scientific, Inc. Announces the Launch of My-Cardia ECG Products and Services in ThailandCB Scientific. Inc. announces the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician. The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed. CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
お知らせ • Sep 24CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp.CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020. CB Scientific, Inc. (OTCPK:CBSC) completed the acquisition of Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.
